39 peer-reviewed studies · Evidence score: 9/10
McFarland LV et al. • Frontiers in cellular and infection microbiology (2025)
S. boulardii CNCM I-745 is an effective treatment for PAGE and was well tolerated in trials done in China.
Li M et al. • Frontiers in cellular and infection microbiology (2025)
S. boulardii supplementation in traditional eradication therapy significantly improves the H. pylori eradication rate and reduces the total adverse effects and incidence of diarrhea, bloating, constipation, and nausea.
Rahman MN et al. • Gut microbes (2024)
Protocol registration: PROSPERO (ID = CRD42021276045).
Liu LH et al. • BMC infectious diseases (2023)
Current evidence indicated that S. boulardii supplementing with STT could improve the eradication rate of H. pylori, and concurrently decrease the incidence of total adverse events and gastrointestinal adverse events in children.
Li Z et al. • Nutrients (2021)
To be conclusive, Saccharomyces boulardii may be the most effective probiotic for treating acute diarrhea in children, followed by several other single-strain and multi-strain probiotics.
Fu H et al. • Computational and mathematical methods in medicine (2022)
The use of probiotic Saccharomyces boulardii can significantly improve the symptoms of diarrhea in children with acute gastroenteritis and reduce the duration of diarrhea symptoms and the time of hospitalization.
Gao X et al. • Journal of tropical pediatrics (2021)
According to this evidence we recommend S. boulardii to prevent NEC, reduce the feeding intolerance, shorten the full feeding days and hospitalization days.
Collinson S et al. • The Cochrane database of systematic reviews (2020)
Probiotics probably make little or no difference to the number of people who have diarrhoea lasting 48 hours or longer, and we are uncertain whether probiotics reduce the duration of diarrhoea.
Zhou BG et al. • Helicobacter (2019)
Our meta-analysis shows that S boulardii supplementation on standard eradication therapy significantly increased H pylori eradication rates and reduced the incidence of total side effects and some gastrointestinal adverse effects during eradication therapy.
Chang HY et al. • PloS one (2017)
This updated report found that multiple strains probiotics appear to be the most feasible and effective strategy for the prevention of NEC and reduction of mortality in PVLBW neonates.
Wang F et al. • Clinics and research in hepatology and gastroenterology (2017)
Compared to placebo, most probiotic strategies were effective when supplemented in Hp eradication therapy.
Szajewska H et al. • Alimentary Pharmacology & Therapeutics (2015)
S. boulardii significantly reduces the risk of antibiotic-associated diarrhea.
Jiang YZ et al. • BMC gastroenterology (2025)
The addition of S. boulardii to bismuth quadruple therapy significantly increased H. pylori eradication rates and decreased the adverse effects.
Liu YH et al. • International journal of antimicrobial agents (2025)
Adding probiotics, particularly S. boulardii or multi-strain combinations, to BQT significantly improves eradication efficacy and decreases treatment-related adverse events.
Alharbi BF et al. • Travel medicine and infectious disease (2024)
Studies investigating probiotics as a preventive measure for TD remain limited.
Anvarifard P et al. • Food & function (2024)
This meta-analysis examined the effects of Saccharomyces Boulardii.
Florez ID et al. • PloS one (2018)
Most interventions analyzed (except vitamin A, micronutrients, prebiotics, and kaolin-pectin) showed evidence of superiority to placebo in reducing the diarrhea.
Losurdo G et al. • World journal of gastroenterology (2018)
Probiotics alone show a minimal effect on H. pylori clearance, thus suggesting a likely direct role.
Sniffen JC et al. • PloS one (2018)
The choice of an appropriate probiotic is multi-factored, based on the mode and type of disease indication and the specific efficacy of probiotic strain(s), as well as product quality and formulation.
Morgan RL et al. • Gastroenterology (2020)
In a systematic review and network meta-analysis of studies to determine the effects of single-strain and multistrain probiotic formulations on outcomes of preterm, low-birth-weight neonates, we found moderate to high evidence for the superiority of combinations of 1 or more Lactobacillus spp and 1 or more Bifidobacterium spp vs single- and other multiple-strain probiotic treatments.